Antares/BioSante start Ph II trial of LibiGel
Antares Pharma and BioSante Pharmaceuticals have initiated a Phase IIclinical trial of the latter's transdermal testosterone gel, LibiGel, which utilizes the former's proprietary advanced gel technology for drug delivery through the skin, in the treatment of female sexual dysfunction caused by testosterone deficiency. The study will be conducted in hysterectomized women with low levels of the hormone. LibiGel delivers testosterone into the bloodstream evenly over time and is based on a gel technology that, according to Antares' chief executive Roger Harrison, is "accurate, easy to apply and discreet."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze